{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T15:19:26Z","timestamp":1787498366942,"version":"build-2736575974"},"reference-count":45,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2016,6,1]],"date-time":"2016-06-01T00:00:00Z","timestamp":1464739200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,6,1]],"date-time":"2016-06-01T00:00:00Z","timestamp":1464739200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["molpharm.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Pharmacology"],"published-print":{"date-parts":[[2016,6]]},"DOI":"10.1124\/mol.115.103200","type":"journal-article","created":{"date-parts":[[2016,3,22]],"date-time":"2016-03-22T22:35:24Z","timestamp":1458686124000},"page":"667-677","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":62,"title":["Synthesis and Evaluation of Potent KCNQ2\/3-Specific Channel Activators"],"prefix":"10.1016","volume":"89","author":[{"given":"Manoj","family":"Kumar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Reed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruiting","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elias","family":"Aizenman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Wipf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thanos","family":"Tzounopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/mol.115.103200_bib1","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1021\/acsmedchemlett.5b00364","article-title":"Structure-activity study of bioisosteric trifluoromethyl and pentafluorosulfanyl indole inhibitors of the AAA ATPase p97","volume":"6","author":"Alverez","year":"2015","journal-title":"ACS Med Chem Lett"},{"key":"10.1124\/mol.115.103200_bib2","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.eplepsyres.2010.09.001","article-title":"Progress report on new antiepileptic drugs: a summary of the Tenth Eilat Conference (EILAT X)","volume":"92","author":"Bialer","year":"2010","journal-title":"Epilepsy Res"},{"key":"10.1124\/mol.115.103200_bib3","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/nrd2997","article-title":"Key factors in the discovery and development of new antiepileptic drugs","volume":"9","author":"Bialer","year":"2010","journal-title":"Nat Rev Drug Discov"},{"key":"10.1124\/mol.115.103200_bib4","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1126\/science.279.5349.403","article-title":"A potassium channel mutation in neonatal human epilepsy","volume":"279","author":"Biervert","year":"1998","journal-title":"Science"},{"key":"10.1124\/mol.115.103200_bib5","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/j.seizure.2010.10.027","article-title":"Antiepileptic drug therapy the story so far","volume":"19","author":"Brodie","year":"2010","journal-title":"Seizure"},{"key":"10.1124\/mol.115.103200_bib6","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/283673a0","article-title":"Muscarinic suppression of a novel voltage-sensitive K+ current in a vertebrate neurone","volume":"283","author":"Brown","year":"1980","journal-title":"Nature"},{"key":"10.1124\/mol.115.103200_bib7","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1111\/j.1476-5381.2009.00111.x","article-title":"Neural KCNQ (Kv7) channels","volume":"156","author":"Brown","year":"2009","journal-title":"Br J Pharmacol"},{"key":"10.1124\/mol.115.103200_bib8","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.ejphar.2013.03.039","article-title":"Characterization of a novel high-potency positive modulator of K(v)7 channels","volume":"709","author":"Dalby-Brown","year":"2013","journal-title":"Eur J Pharmacol"},{"key":"10.1124\/mol.115.103200_bib9","doi-asserted-by":"crossref","first-page":"4941","DOI":"10.1016\/j.bmcl.2015.04.074","article-title":"Discovery of a novel Kv7 channel opener as a treatment for epilepsy","volume":"25","author":"Davoren","year":"2015","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1124\/mol.115.103200_bib10","doi-asserted-by":"crossref","first-page":"4132","DOI":"10.1128\/AAC.00631-06","article-title":"Utility of alkylaminoquinolinyl methanols as new antimalarial drugs","volume":"50","author":"Dow","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1124\/mol.115.103200_bib11","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1111\/j.1476-5381.2009.00131.x","article-title":"New tricks for old dogs: KCNQ expression and role in smooth muscle","volume":"156","author":"Greenwood","year":"2009","journal-title":"Br J Pharmacol"},{"key":"10.1124\/mol.115.103200_bib12","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1517\/14728222.12.5.565","article-title":"The therapeutic potential of neuronal K V 7 (KCNQ) channel modulators: an update","volume":"12","author":"Gribkoff","year":"2008","journal-title":"Expert Opin Ther Targets"},{"key":"10.1124\/mol.115.103200_bib13","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.ejphar.2014.01.017","article-title":"Kv7 channels as targets for anti-epileptic and psychiatric drug-development","volume":"726","author":"Grunnet","year":"2014","journal-title":"Eur J Pharmacol"},{"key":"10.1124\/mol.115.103200_bib14","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1111\/j.1528-1167.2011.03365.x","article-title":"The mechanism of action of retigabine (ezogabine), a first-in-class K+ channel opener for the treatment of epilepsy","volume":"53","author":"Gunthorpe","year":"2012","journal-title":"Epilepsia"},{"key":"10.1124\/mol.115.103200_bib15","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1113\/jphysiol.2007.149450","article-title":"Kv7 channels: interaction with dopaminergic and serotonergic neurotransmission in the CNS","volume":"586","author":"Hansen","year":"2008","journal-title":"J Physiol"},{"key":"10.1124\/mol.115.103200_bib16","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.neuron.2007.02.010","article-title":"Structural insight into KCNQ (Kv7) channel assembly and channelopathy","volume":"53","author":"Howard","year":"2007","journal-title":"Neuron"},{"key":"10.1124\/mol.115.103200_bib17","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1091\/mbc.e11-12-1044","article-title":"Specification of skeletal muscle differentiation by repressor element-1 silencing transcription factor (REST)-regulated Kv7.4 potassium channels","volume":"24","author":"Iannotti","year":"2013","journal-title":"Mol Biol Cell"},{"key":"10.1124\/mol.115.103200_bib18","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1124\/jpet.109.162800","article-title":"Expression, localization, and pharmacological role of Kv7 potassium channels in skeletal muscle proliferation, differentiation, and survival after myotoxic insults","volume":"332","author":"Iannotti","year":"2010","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/mol.115.103200_bib19","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1517\/17460441.2013.837882","article-title":"The preclinical discovery and development of ezogabine for the treatment of epilepsy","volume":"8","author":"Jankovic","year":"2013","journal-title":"Expert Opin Drug Discov"},{"key":"10.1124\/mol.115.103200_bib20","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/35036198","article-title":"Neuronal KCNQ potassium channels: physiology and role in disease","volume":"1","author":"Jentsch","year":"2000","journal-title":"Nat Rev Neurosci"},{"key":"10.1124\/mol.115.103200_bib21","doi-asserted-by":"crossref","first-page":"8829","DOI":"10.1523\/JNEUROSCI.5176-14.2015","article-title":"Potent KCNQ2\/3-specific channel activator suppresses in vivo epileptic activity and prevents the development of tinnitus","volume":"35","author":"Kalappa","year":"2015","journal-title":"J Neurosci"},{"key":"10.1124\/mol.115.103200_bib22","doi-asserted-by":"crossref","first-page":"5537","DOI":"10.1016\/j.bmcl.2007.08.033","article-title":"Structure-activity relationship study of novel NR2B-selective antagonists with arylamides to avoid reactive metabolites formation","volume":"17","author":"Kawai","year":"2007","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1124\/mol.115.103200_bib23","doi-asserted-by":"crossref","first-page":"4333","DOI":"10.1073\/pnas.97.8.4333","article-title":"KCNQ4, a K+ channel mutated in a form of dominant deafness, is expressed in the inner ear and the central auditory pathway","volume":"97","author":"Kharkovets","year":"2000","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1124\/mol.115.103200_bib24","doi-asserted-by":"crossref","first-page":"8116","DOI":"10.1038\/ncomms9116","article-title":"Atomic basis for therapeutic activation of neuronal potassium channels","volume":"6","author":"Kim","year":"2015","journal-title":"Nat Commun"},{"key":"10.1124\/mol.115.103200_bib25","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1124\/mol.108.052282","article-title":"Refinement of the binding site and mode of action of the anticonvulsant Retigabine on KCNQ K+ channels","volume":"75","author":"Lange","year":"2009","journal-title":"Mol Pharmacol"},{"key":"10.1124\/mol.115.103200_bib26","doi-asserted-by":"crossref","first-page":"9980","DOI":"10.1073\/pnas.1302770110","article-title":"Pathogenic plasticity of Kv7.2\/3 channel activity is essential for the induction of tinnitus","volume":"110","author":"Li","year":"2013","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1124\/mol.115.103200_bib27","doi-asserted-by":"crossref","first-page":"4","DOI":"10.7554\/eLife.07242","article-title":"Noise-induced plasticity of KCNQ2\/3 and HCN channels underlies vulnerability and resilience to tinnitus","volume":"4","author":"Li","year":"2015","journal-title":"eLife"},{"key":"10.1124\/mol.115.103200_bib28","doi-asserted-by":"crossref","first-page":"9825","DOI":"10.1523\/JNEUROSCI.2597-05.2005","article-title":"Regulation of Kv7 (KCNQ) K+ channel open probability by phosphatidylinositol 4,5-bisphosphate","volume":"25","author":"Li","year":"2005","journal-title":"J Neurosci"},{"key":"10.1124\/mol.115.103200_bib29","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.coph.2007.10.003","article-title":"Molecular pharmacology and therapeutic potential of neuronal Kv7-modulating drugs","volume":"8","author":"Miceli","year":"2008","journal-title":"Curr Opin Pharmacol"},{"key":"10.1124\/mol.115.103200_bib30","doi-asserted-by":"crossref","first-page":"5137","DOI":"10.1016\/j.tetlet.2010.07.113","article-title":"Synthesis of an 8-pentafluorosulfanyl analog of the antimalarial agent mefloquine","volume":"51","author":"Mo","year":"2010","journal-title":"Tetrahedron Lett"},{"key":"10.1124\/mol.115.103200_bib31","doi-asserted-by":"crossref","first-page":"2576","DOI":"10.1021\/jm060989l","article-title":"Kv7 (KCNQ) channel modulators and neuropathic pain","volume":"50","author":"Munro","year":"2007","journal-title":"J Med Chem"},{"key":"10.1124\/mol.115.103200_bib32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0163-7258(01)00116-4","article-title":"KCNQ potassium channels: physiology, pathophysiology, and pharmacology","volume":"90","author":"Robbins","year":"2001","journal-title":"Pharmacol Ther"},{"key":"10.1124\/mol.115.103200_bib33","doi-asserted-by":"crossref","first-page":"5051","DOI":"10.1523\/JNEUROSCI.0128-05.2005","article-title":"Molecular determinants of KCNQ (Kv7) K+ channel sensitivity to the anticonvulsant retigabine","volume":"25","author":"Schenzer","year":"2005","journal-title":"J Neurosci"},{"key":"10.1124\/mol.115.103200_bib34","doi-asserted-by":"crossref","first-page":"1","DOI":"10.14581\/jer.15001","article-title":"Pharmacoresistant epilepsy: a current update on non-conventional pharmacological and non-pharmacological interventions","volume":"5","author":"Sharma","year":"2015","journal-title":"J Epilepsy Res"},{"key":"10.1124\/mol.115.103200_bib35","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1021\/ml5001504","article-title":"An uncharged oxetanyl sulfoxide as a covalent modifier for improving aqueous solubility","volume":"5","author":"Skoda","year":"2014","journal-title":"ACS Med Chem Lett"},{"key":"10.1124\/mol.115.103200_bib36","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1124\/mol.110.066100","article-title":"The specific slow afterhyperpolarization inhibitor UCL2077 is a subtype-selective blocker of the epilepsy associated KCNQ channels","volume":"78","author":"Soh","year":"2010","journal-title":"Mol Pharmacol"},{"key":"10.1124\/mol.115.103200_bib37","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1089\/adt.2011.0421","article-title":"A bifunctional dimethylsulfoxide substitute enhances the aqueous solubility of small organic molecules","volume":"10","author":"Sprachman","year":"2012","journal-title":"Assay Drug Dev Technol"},{"key":"10.1124\/mol.115.103200_bib38","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.drudis.2013.12.003","article-title":"K(V)7 potassium channels: a new therapeutic target in smooth muscle disorders","volume":"19","author":"Stott","year":"2014","journal-title":"Drug Discov Today"},{"key":"10.1124\/mol.115.103200_bib39","doi-asserted-by":"crossref","first-page":"5535","DOI":"10.1523\/JNEUROSCI.21-15-05535.2001","article-title":"Activation of expressed KCNQ potassium currents and native neuronal M-type potassium currents by the anti-convulsant drug retigabine","volume":"21","author":"Tatulian","year":"2001","journal-title":"J Neurosci"},{"issue":"Suppl 7","key":"10.1124\/mol.115.103200_bib40","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/j.1528-1167.2011.03121.x","article-title":"Standards for epidemiologic studies and surveillance of epilepsy","volume":"52","author":"Thurman","year":"2011","journal-title":"Epilepsia"},{"key":"10.1124\/mol.115.103200_bib41","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.2174\/138161209788186326","article-title":"Kv7 channels as targets for the treatment of pain","volume":"15","author":"Wickenden","year":"2009","journal-title":"Curr Pharm Des"},{"key":"10.1124\/mol.115.103200_bib42","doi-asserted-by":"crossref","first-page":"4163","DOI":"10.1039\/b911483a","article-title":"Synthesis and biological evaluation of the first pentafluorosulfanyl analogs of mefloquine","volume":"7","author":"Wipf","year":"2009","journal-title":"Org Biomol Chem"},{"key":"10.1124\/mol.115.103200_bib43","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1038\/nrd2983","article-title":"Voltage-gated potassium channels as therapeutic targets","volume":"8","author":"Wulff","year":"2009","journal-title":"Nat Rev Drug Discov"},{"key":"10.1124\/mol.115.103200_bib44","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1124\/mol.104.010793","article-title":"The new anticonvulsant retigabine favors voltage-dependent opening of the Kv7.2 (KCNQ2) channel by binding to its activation gate","volume":"67","author":"Wuttke","year":"2005","journal-title":"Mol Pharmacol"},{"key":"10.1124\/mol.115.103200_bib45","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.tips.2007.11.010","article-title":"Activation of Kv7 (KCNQ) voltage-gated potassium channels by synthetic compounds","volume":"29","author":"Xiong","year":"2008","journal-title":"Trends Pharmacol Sci"}],"container-title":["Molecular Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026895X2400484X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026895X2400484X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/mol.115.103200","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T05:00:42Z","timestamp":1739941242000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0026895X2400484X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6]]},"references-count":45,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2016,6]]}},"alternative-id":["S0026895X2400484X"],"URL":"https:\/\/doi.org\/10.1124\/mol.115.103200","relation":{},"ISSN":["0026-895X"],"issn-type":[{"value":"0026-895X","type":"print"}],"subject":[],"published":{"date-parts":[[2016,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Synthesis and Evaluation of Potent KCNQ2\/3-Specific Channel Activators","name":"articletitle","label":"Article Title"},{"value":"Molecular Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/mol.115.103200","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}